Citations

Clear

6273 citation(s) found for "To, Andrew".

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma
Trippa, Lorenzo , Gaffey, Sarah, Arrillaga‐Romany, Isabel , Lee, Eudocia Q. , Rinne, Mikael L. , Ahluwalia, Manmeet S. , Colman, Howard , Fell, Geoffrey, Lassman, Andrew B. , Meredith, David M. , Schiff, David , Welch, Mary , Wen, Patrick Y. , Galanis, Evanthia , Ahluwalia, Manmeet S , Alexander, Brian M. , Arrillaga‐Romany, Isabel , Colman, Howard , Fell, Geoffrey G. , Groot, John de , Drappatz, Jan , Nabors, Burt , Santagata, Sandro , Ligon, Keith L , Wen, Patrick Yung

Mayo Clinic

JCO Precision Oncology | March 27, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-13

10.1200/po.18.00071 | PMID 32914038 Get It

PURPOSE Adequately prioritizing the numerous therapies and biomarkers available in late-stage testing for patients with glioblastoma (GBM) requires an efficient clinical testing platform. We developed and implemented INSIGhT (Individualized Screening Trial of Innovative Glioblastoma Therapy) as a novel adaptive platform trial (APT) to develop precision medicine approaches in GBM. METHODS INSIGhT compares experimental arms with a common control of standard concurrent temozolomide and radiation therapy followed by adjuvant temozolomide. The primary end point is overall survival. Patients with newly diagnosed unmethylated GBM who are IDH R132H mutation negative and with genomic data available for biomarker grouping are eligible. At the initiation of INSIGhT, three experimental arms (neratinib, abemaciclib, and CC-115), each with a proposed genomic biomarker, are tested simultaneously. Initial randomization is equal across arms. As the trial progresses, randomization probabilities adapt on the basis of accumulating results using Bayesian estimation of the biomarker-specific probability of treatment impact on progression-free survival. Treatment arms may drop because of low probability of treatment impact on overall survival, and new arms may be added. Detailed information on the statistical model and randomization algorithm is provided to stimulate discussion on trial design choices more generally and provide an example for other investigators developing APTs. CONCLUSION INSIGhT (NCT02977780) is an ongoing novel biomarker-based, Bayesian APT for patients with newly diagnosed unmethylated GBM. Our goal is to dramatically shorten trial execution timelines while increasing scientific power of results and biomarker discovery using adaptive randomization. We anticipate that trial execution efficiency will also be improved by using the APT format, which allows for the collaborative addition of new experimental arms while retaining the overall trial structure.
Reply to: ‘Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis’
Lapumnuaypol, Kamolyut , Tiu, Andrew , Thongprayoon, Charat , Wijarnpreecha, Karn , Ungprasert, Patompong , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Thongprayoon, Charat , Wijarnpreecha, Karn , Mao, Michael A.

Mayo Clinic

QJM: An International Journal of Medicine | March 24, 2019 | Volume: 112 | Issue: 8 | Pages: 645-645

10.1093/qjmed/hcz075 | PMID 30907969 Get It

Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
Tempero, Margaret A. , Malafa, Mokenge P. , Chiorean, E Gabriela, Czito, Brian G. , Scaife, Courtney, Narang, Amol K, Fountzilas, Christos, Wolpin, Brian M. , Al-Hawary, Mahmoud, Asbun, Horacio, Behrman, Stephen W. , Benson, Al B. , Binder, Ellen, Cardin, Dana B, Cha, Charles, Chung, Vincent, Dillhoff, Mary, Dotan, Efrat, Ferrone, Cristina R, Fisher, George, Hardacre, Jeffrey, Ko, Andrew H. , LoConte, Noelle, Lowy, Andrew M, Moravek, Cassadie, Nakakura, Eric K. , O'Reilly, Eileen M, Obando, Jorge, Reddy, Sushanth, Thayer, Sarah P. , Wolff, Robert A. , Burns, Jennifer L, Zuccarino-Catania, Griselda, LoConte, Noelle K. , Chung, Vincent , Cardin, Dana B. , O’Reilly, Eileen M. , Fountzilas, Christos , Cha, Charles , Cardin, Dana B , LoConte, Noelle , O'Reilly, Eileen M , Chung, Vincent , Chiorean, E Gabriela, Scaife, Courtney, Narang, Amol K, Fountzilas, Christos, Al-Hawary, Mahmoud, Asbun, Horacio, Binder, Ellen, Cardin, Dana B, Cha, Charles, Chung, Vincent, Dillhoff, Mary, Dotan, Efrat, Ferrone, Cristina R, Fisher, George, Hardacre, Jeffrey, Hawkins, William G , LoConte, Noelle, Lowy, Andrew M, Moravek, Cassadie, O'Reilly, Eileen M, Reddy, Sushanth, Burns, Jennifer L, Zuccarino-Catania, Griselda

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 202-210

10.6004/jnccn.2019.0014 | PMID 30865919 Get It

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.
Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells
Chen, Yi‐Bin , Brazauskas, Ruta , Kiefer, Deidre M., Litzow, Mark R. , Horwitz, Mitchell E. , McClune, Brian , Fernández, Hugo F. , Duong, Hien K., Kobusingye, Hati, Proue, Mandi, Drexler, Rebecca, Horowitz, Mary M. , Shaw, Bronwen E. , Hosoba, Sakura, Waller, Edmund K. , Waller, Edmund K , Le‐Rademacher, Jennifer , Hamadani, Mehdi , DiPersio, John F. , Craig, Michael , Artz, Andrew , Miller, J. Philip , Devine, Steven M.

Mayo Clinic

Blood Advances | March 19, 2019 | Volume: 3 | Issue: 6 | Pages: 875-883

10.1182/bloodadvances.2018027599 | PMID 30890544 Get It

Abstract Plerixafor, a direct antagonist of CXCR4/stromal-derived factor 1, can safely and rapidly mobilize allografts without the use of granulocyte colony-stimulating factor (G-CSF). We conducted a phase 2, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts for allogeneic hematopoietic cell transplantation in recipients with hematological malignancies. Donors (n = 64) were treated with subcutaneous plerixafor (240 µg/kg) and started leukapheresis (LP) 4 hours later. The primary objective was to determine the proportion of donors who were successfully mobilized: defined as collection of ≥2.0 × 106 CD34+ cells per kilogram recipient weight in ≤2 LP sessions. Recipients subsequently received reduced intensity (RIC; n = 33) or myeloablative (MAC; n = 30) conditioning. Sixty-three of 64 (98%) donors achieved the primary objective. The median CD34+ cell dose per kilogram recipient weight collected within 2 days was 4.7 (0.9-9.6). Plerixafor was well tolerated with only grade 1 or 2 drug-related adverse events noted. Bone pain was not observed. Plerixafor-mobilized grafts engrafted promptly. One-year progression-free and overall survivals were 53% (95% confidence interval [CI], 36% to 71%) and 63% (95% CI, 46% to 79%) for MAC and 64% (95% CI, 47% to 79%) and 70% (95% CI, 53% to 84%) for RIC recipients, respectively. Donor toxicity was reduced relative to G-CSF mobilized related donors. This is the first multicenter trial to demonstrate that, as an alternative to G-CSF, plerixafor rapidly and safely mobilizes sufficient numbers of CD34+ cells from matched sibling donors for HCT. Engraftment was prompt, and outcomes in recipients were encouraging. This trial was registered at clinicaltrials.gov as #NCT01696461.
Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines
Chang, Susan M. , Messersmith, Hans , Ahluwalia, Manmeet S. , Gaspar, Laurie E., Gatson, Na Tosha , Khasraw, Mustafa , Lassman, Andrew B. , Maués, Julia , Mrugała, Maciej M. , Raizer, Jeffrey J. , Schiff, David , Stevens, Glen , Sumrall, Ashley , Bent, Martin J. van den , Vogelbaum, Michael A. , van den Bent, Martin J , Khasraw, Mustafa , Gatson, Na Tosha N , Messersmith, Hans , Sumrall, Ashley , Ahluwalia, Manmeet S , Chang, Susan Marina , Andrews, David William , Brastianos, Priscilla K. , Jordan, Justin T.

Mayo Clinic

Journal of Clinical Oncology | March 18, 2019 | Volume: 37 | Issue: 13 | Pages: 1130-1135

10.1200/jco.18.02085 | PMID 30883246 Get It

PURPOSE The Congress of Neurological Surgeons (CNS) has developed a series of guidelines for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS Two CNS guidelines were reviewed for developmental rigor by methodologists, and an independent multidisciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. The Expert Panel voted to endorse the two guidelines, and ASCO and Society for Neuro-Oncology (SNO) independently reviewed and approved the ASCO/SNO guideline endorsement. RESULTS The ASCO/SNO Expert Panel determined that the recommendations from the CNS anticonvulsants and steroids guidelines, published January 9, 2019, are clear, thorough, and based on the most relevant scientific evidence. ASCO/SNO endorsed these two CNS guidelines with minor alterations. RECOMMENDATIONS Key recommendations include the following: prophylactic antiepileptic drugs were not recommended for routine use; and corticosteroids, specifically dexamethasone, were recommended for temporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect from brain metastases. Additional information is available at www.asco.org/neurooncology-guidelines .
Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)
Kiely, David G. , Levin, David L. , Ivy, D. Dunbar , Bwika, Jumaa, Lordan, Jim , Mazurek, Jeremy A. , Moledina, Shahin , Olschewski, Horst , Peacock, Andrew J. , Puri, G. D., Rahaghi, Farbod N. , Schäfer, Michal , Screaton, Nicholas, Noordegraaf, Anton Vonk , Vandepool, Rebecca, Wort, Stephen J. , Zhao, Lan , Wild, Jim M. , Vogel‐Claussen, Jens , Swift, Andrew J. , Vanderpool, Rebecca , Levin, David, Olschewski, Horst , Vonk Noordegraaf, Anton , Vanderpool, Rebecca R , Wild, Jim M , Hassoun, Paul M. , Jone, Pei-Ni , Kawut, Steven M. , Lungu, Angela , Schiebler, Mark , Tawhai, Merryn Howatson , Beek, Edwin J.R. van , Kiely, David , Vogel-Claussen, Jens

Mayo Clinic

Pulmonary Circulation | March 18, 2019 | Volume: 9 | Issue: 3 | Pages: 1-32

10.1177/2045894019841990 | PMID 30880632 Get It

Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it remains a life‐shortening condition. There have been significant advances in imaging technologies, but despite evidence of their potential clinical utility, practice remains variable, dependent in part on imaging availability and expertise. This statement summarizes current and emerging imaging modalities and their potential role in the diagnosis and assessment of suspected PH. It also includes a review of commonly encountered clinical and radiological scenarios, and imaging and modeling‐based biomarkers. An expert panel was formed including clinicians, radiologists, imaging scientists, and computational modelers. Section editors generated a series of summary statements based on a review of the literature and professional experience and, following consensus review, a diagnostic algorithm and 55 statements were agreed. The diagnostic algorithm and summary statements emphasize the key role and added value of imaging in the diagnosis and assessment of PH and highlight areas requiring further research.
Epidemiology of Shock in Contemporary Cardiac Intensive Care Units
Berg, David D. , Bohula, Erin A. , Katz, Jason N. , Alviar, Carlos L. , Baird-Zars, Vivian M., Barsness, Gregory W. , Burke, James A. , Cremer, Paul , Cruz, Jennifer , Daniels, Lori B. , DeFilippis, Andrew P. , Haleem, Affan , Hollenberg, Steven M. , Horowitz, James M. , Keller, Norma, Kontos, Michael C. , Lawler, Patrick R. , Menon, Venu , Metkus, Thomas S. , Ng, Jason, Orgel, Ryan, Overgaard, Christopher B., Park, Jeong-Gun, Phreaner, Nicholas , Roswell, Robert O. , Schulman, Steven P. , Snell, R. Jeffrey, Solomon, Michael A. , Ternus, Bradley , Tymchak, Wayne , Vikram, Fnu, Morrow, David A. , Lawler, Patrick , Solomon, Michael A , Morrow, David A , Roswell, Robert O , Daniels, Lori B , Bohula, Erin A , Cremer, Paul C , Berg, David , Diepen, Sean van , Barnett, Christopher F. , Burke, James A., Park, Jeong‐Gun

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 16, 2019 | Volume: 12 | Issue: 3 | Pages: No page available

10.1161/circoutcomes.119.005618 | PMID 30879324 Get It

Background Clinical investigations of shock in cardiac intensive care units (CICUs) have primarily focused on acute myocardial infarction (AMI) complicated by cardiogenic shock (AMICS). Few studies have evaluated the full spectrum of shock in contemporary CICUs. Methods and Results The Critical Care Cardiology Trials Network is a multicenter network of advanced CICUs in North America. Anytime between September 2017 and September 2018, each center (n=16) contributed a 2-month snap-shot of all consecutive medical admissions to the CICU. Data were submitted to the central coordinating center (TIMI Study Group, Boston, MA). Shock was defined as sustained systolic blood pressure <90 mm Hg with end-organ dysfunction ascribed to the hypotension. Shock type was classified by site investigators as cardiogenic, distributive, hypovolemic, or mixed. Among 3049 CICU admissions, 677 (22%) met clinical criteria for shock. Shock type was varied, with 66% assessed as cardiogenic shock (CS), 7% as distributive, 3% as hypovolemic, 20% as mixed, and 4% as unknown. Among patients with CS (n=450), 30% had AMICS, 18% had ischemic cardiomyopathy without AMI, 28% had nonischemic cardiomyopathy, and 17% had a cardiac cause other than primary myocardial dysfunction. Patients with mixed shock had cardiovascular comorbidities similar to patients with CS. The median CICU stay was 4.0 days (interquartile range [IQR], 2.5–8.1 days) for AMICS, 4.3 days (IQR, 2.1–8.5 days) for CS not related to AMI, and 5.8 days (IQR, 2.9–10.0 days) for mixed shock versus 1.9 days (IQR, 1.0–3.6) for patients without shock ( P <0.01 for each). Median Sequential Organ Failure Assessment scores were higher in patients with mixed shock (10; IQR, 6–13) versus AMICS (8; IQR, 5–11) or CS without AMI (7; IQR, 5–11; each P <0.01). In-hospital mortality rates were 36% (95% CI, 28%–45%), 31% (95% CI, 26%–36%), and 39% (95% CI, 31%–48%) in AMICS, CS without AMI, and mixed shock, respectively. Conclusions The epidemiology of shock in contemporary advanced CICUs is varied, and AMICS now represents less than one-third of all CS. Despite advanced therapies, mortality in CS and mixed shock remains high. Investigation of management strategies and new therapies to treat shock in the CICU should take this epidemiology into account.
Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer
Fritz, Andrew J. , Gerrard, Diana L., Hong, David I. , Rose, Joshua T., Ghule, Prachi N. , Bolf, Eric L. , Gordon, Jonathan , Tracy, Kirsten M. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Heath, Jessica L. , Frietze, Seth , Zaidi, Sayyed K. , Carr, Frances E. , Lian, Jane B. , Stein, Janet L. , Fritz, A J , Stein, Gary S , van Wijnen, Andre J , Tracy, Kirsten M , Gillis, Noelle E. , Rodriguez, Princess D. , Hong, D., Gordon, J.A., Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Genes, Chromosomes and Cancer | March 15, 2019 | Volume: 58 | Issue: 7 | Pages: 484-499

10.1002/gcc.22731 | PMID 30873710 Get It

Cells establish and sustain structural and functional integrity of the genome to support cellular identity and prevent malignant transformation. In this review, we present a strategic overview of epigenetic regulatory mechanisms including histone modifications and higher order chromatin organization (HCO) that are perturbed in breast cancer onset and progression. Implications for dysfunctions that occur in hormone regulation, cell cycle control, and mitotic bookmarking in breast cancer are considered, with an emphasis on epithelial‐to‐mesenchymal transition and cancer stem cell activities. The architectural organization of regulatory machinery is addressed within the contexts of translating cancer‐compromised genomic organization to advances in breast cancer risk assessment, diagnosis, prognosis, and identification of novel therapeutic targets with high specificity and minimal off target effects.
Identification of high‐risk DUSP 22 ‐rearranged ALK ‐negative anaplastic large ce
Hapgood, Greg , Mottok, Anja , Lee, Derrick G. , Kridel, Robert , Villa, Diego , Gascoyne, Randy D. , Farinha, Pedro , Slack, Graham W. , Villa, Diego , Savage, Kerry J , Farinha, Pedro , Ben‐Neriah, Susana , Kridel, Robert , Sehn, Laurie H. , Connors, Joseph M. , Feldman, Andrew L. , Steidl, Christian , Scott, David W. , Savage, Kerry J.

Mayo Clinic

British Journal of Haematology | March 14, 2019 | Volume: 186 | Issue: 3 | Pages: No page available

10.1111/bjh.15860 | PMID 30873584 Get It